Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma

Raffaele Pezzilli, MD, Gian Vico Melzì d’Eril, MD, and Alessandra Barassi, MD

Abstract: There are no studies comparing some of the most important markers, such as vitamin D, parathormone, osteocalcin, bone alkaline phosphatase, and calcium, in patients with chronic benign and malignant pancreatic diseases. Our objective was to comparatively evaluate serum markers of bone metabolism in patients with chronic pancreatitis and in those with ductal pancreatic adenocarcinoma. Sixty-three consecutive subjects were studied: 30 patients with a firm diagnosis of chronic pancreatitis and 33 having histologically confirmed pancreatic adenocarcinoma. Serum 25-hydroxyvitamin D, bone alkaline phosphatase, osteocalcin, parathormone, and calcium were determined using commercially available kits. Taking into consideration the clinical variables of all 63 patients studied, 25-hydroxyvitamin D was inversely correlated with only the body mass index (P = 0.007), whereas it was not correlated with age (P = 0.583) or fecal elastase-1 concentrations (P = 0.556). Regarding the other substances studied, parathormone was positively correlated with only the age of the patients (P = 0.015). Of the 5 substances studied, only bone alkaline phosphates were significantly different (P < 0.001) between patients with chronic pancreatitis and those with pancreatic ductal adenocarcinoma. Within the 2 groups of patients, the 23 patients with chronic pancreatitis without diabetes mellitus had serum concentrations of 25-hydroxyvitamin D significantly lower (P = 0.045) than those with chronic pancreatitis having diabetes mellitus, whereas smokers with pancreatic ductal adenocarcinoma had serum concentrations of calcium significantly higher (P < 0.001) as compared to nonsmokers. Altered bone metabolism seems to be associated with chronic diseases of the pancreas; however, the mechanism should be better elucidated.

(IN)TRODUCTION

Vitamin D together with vitamins A, E, and K are liposoluble substances and require pancreatic enzymes to be absorbed by the intestinal tract; vitamin D exerts broad-ranging effects on muscle and bone calcium handling, differentiation, and development; it also modulates muscle and bone-derived hormones, potentially facilitating cross-talk between these tissues. In a clinical setting, vitamin D deficiency results in generalized atrophy of muscle and bone, suggesting coordinated effects of vitamin D at these sites. Parathormone (PHT) is a hormone secreted by the parathyroid cells; it elevates the blood calcium level by dissolving the salts in bone and preventing their renal excretion. Osteocalcin is the major noncollagenous bone protein and is regarded as a specific index of bone formation. Bone alkaline phosphatase is a measure of bone formation. Measuring the biochemical markers of bone metabolism could lead to a better understanding of the transition of bone in chronic diseases of the pancreas; in fact, the isolation and characterization of both the cellular and the extracellular components of the skeletal matrix results in the development of molecular markers, which are considered to reflect either bone formation or bone resorption. In addition, these biochemical indices are noninvasive, have a low cost, and may be obtained routinely; they are helpful tools in the diagnostic and therapeutic assessment of metabolic bone disease. There are no studies comparing some of the most important markers, such as vitamin D, PTH, osteocalcin, bone alkaline phosphatase, and calcium, in patients with chronic benign and malignant pancreatic diseases. Thus, the aim of our study was to comparatively evaluate serum markers of bone metabolism in patients with chronic pancreatitis and in those with ductal pancreatic adenocarcinoma.

SUBJECTS AND METHODS

From January 2014 to December 2015, 63 consecutive subjects were studied: 30 patients with a firm diagnosis of chronic pancreatitis (based on clinical history characterized by recurrent pain associated with imaging compatible with features of chronic pancreatitis associated or not with the presence of exocrine pancreatic insufficiency), and 33 having histologically confirmed pancreatic adenocarcinoma.

Ten patients with established diagnosis of osteoporosis/osteopenia, those treated with drugs for osteoporosis/osteopenia, those with known hypogonadism, and those with renal or hepatic insufficiency, were excluded from the study.

The clinical characteristics of the patients studied are reported in Table 1. An alcohol drinker was defined when a subject actively consumes >80 g of pure alcohol per day for at least 5 years, and a smoker as a subject smoking any quantity of tobacco for at least 5 years; a patient was classified having pain when a typical pancreatic pain was present during the last 7 days before his entry into the study. From all patients, the blood samples were taken at the time of diagnosis, after informed consent was obtained. The study was approved by the Department of Digestive System of Sant’Orsola-Malpighi Hospital, Bologna, Italy, and the examinations performed are those routinely performed in these patients.

Serum 25-hydroxyvitamin D levels were measured using a chemiluminescence assay (25 OH Vitamin D TOTAL
Variable | Chronic Pancreatitis n = 30 | PDAC n = 33 | Total n = 63 | P Value |
--- | --- | --- | --- | --- |
Gender | Male | 15 | 50.0 | 21 | 63.6 | 36 | 57.1 | 0.316 |
| Female | 15 | 50.0 | 12 | 36.3 | 27 | 42.9 |
Age, y | 57.0 ± 13.1 | 65.1 ± 8.9 | 61.2 ± 11.7 | P = 0.005 |
BMI, kg/m² | 23.5 ± 2.2 | 23.8 ± 3.6 | 23.6 ± 3.0 | 0.752 |
BMI classes | Underweight | 1 | 3.3 | 3 | 9.1 | 4 | 6.3 | 0.204 |
| Normal weight | 24 | 80.0 | 19 | 57.6 | 43 | 68.3 |
| Overweight | 5 | 16.6 | 9 | 27.3 | 14 | 22.2 |
| Obese | 0 | – | 2 | 6.1 | 2 | 3.2 |
Alcohol drinkers | Yes | 16 | 53.3 | 5 | 15.2 | 21 | 33.2 | 0.03 |
Smokers | Yes | 15 | 50.0 | 6 | 45.5 | 21 | 33.3 | 0.015 |
Diabetes | Yes | 8 | 26.7 | 33 | 100.0 | 41 | 65.1 | <0.001 |
Calcifications | Yes | 7 | 23.3 | 17 | 70.8 | 24 | 38.1 | 0.021 |
EPI | Yes | 15 | 50.0 | 15 | 51.5 | 15 | 23.8 | <0.001 |
Imaging | Yes | 30 | 100.0 | 33 | 100.0 | 63 | 100.0 | 1.000 |
Histology | Yes | 4 | 13.3 | 33 | 100.0 | 37 | 58.7 | <0.001 |
Surgery | Yes | 2 | 6.7 | 6 | 18.2 | 8 | 12.7 | 0.170 |
Tumor site | Pancreas head | – | – | 30 | 90.9 |
| Pancreas body | – | – | 3 | 9.1 |
Metastases | Yes | – | – | 15 | 45.5 |

Alcohol drinkers: patients drink >80 g pure alcohol per day. BMI = body mass index, EPI = exocrine pancreatic insufficiency, PDAC = pancreatic ductal adenocarcinoma. Percentages calculated within the group of patients with pancreatic ductal adenocarcinoma.

Assay, DiaSorin, Saluggia, Italy). The within-run coefficient of variation (CV) was 3.7 to 7.7%; and the total imprecision CV was 5.8 to 10.9%; the detection limit of the assay was 4 ng/mL. For the quantitative determination of bone alkaline phosphatase, a direct, 2-site sandwich-type immunoluminometric assay was utilized using 2 monoclonal antibodies (BAP OSTASE, DiaSorin, Saluggia, Italy). The within-run coefficient of variation was 3.2 to 4.0% and the total imprecision CV was 6.5 to 8.1%; the detection limit of the assay was 1.5 μg/L. Osteocalcin was assayed using a direct, 2-site, sandwich-type immunoluminometric assay with directly coated magnetic microparticles (Osteocalcin, DiaSorin, Saluggia, Italy). The within-run coefficient of variation was 3.0 to 8.0% and the total imprecision CV was 4.0 to 9.0%; the detection limit of the assay was 0.5 ng/mL. For the quantitative determination of 1 to 84 PTH without a cross-reaction to 7 to 84 and other PTH fragments, a direct, 2-site, sandwich-type immunoluminometric assay utilizing directly coated magnetic microparticles was used (1–84 PTH Assay, DiaSorin, Saluggia, Italy). The within-run coefficient of variation was 3.0 to 5.9% and the total imprecision CV was 5.5 to 9.0%; the detection limit of the assay was 4 pg/mL. All these assays were carried out using the LIAISON Analyzer (DiaSorin, Saluggia, Italy). Calcium was determined using a colorimetric method (VITROS Chemistry Products Ca Slides, Ortho Clinical Diagnostics, Rochester). The within-run coefficient of variation was 0.04 to 0.12% and the total imprecision CV was 0.9 to 1.9%; the detection limit of the assay was 4 mg/dL. The test runs were carried out using Vitros 5600 (VITROS 5600 Integrated System, Ortho Clinical Diagnostics, Rochester).

The reference values of the various substances evaluated were as follows: 25-hydroxyvitamin D: <20.0 ng/mL was adopted as ‘‘deficient’’, between 20.0 and 30.0 ng/mL as ‘‘insufficient’’ whereas optimal levels were defined as vitamin D >30.0 ng/mL; osteocalcin in men 4.6 to 65.4 ng/mL and in women 6.5 to 42.3 ng/mL during the premenopausal age and 6.5 to 59.1 ng/mL during the postmenopausal age, PTH: 4.6 to 58.1 pg/mL, bone alkaline phosphatase 5.5 to 24.6 μg/L and calcium 8.4 to 10.2 mg/dL. Finally, fecal pancreatic elastase-1, as a marker of exocrine pancreatic insufficiency (ScheBo Biotech AG, Giessen, Germany), the within-run CV 6.4%, the total imprecision CV 8.8%, and the detection limit 15 μg/g; values <200 μg/g were considered to be the index of exocrine pancreatic insufficiency.

Statistical Analysis

Serum 25-hydroxyvitamin D levels and calcium concentration were normally distributed in our study population; on the other hand, osteocalcin, bone alkaline phosphatases, and PTH were not normally distributed, and their values were normalized using lognormal transformation. Thus, for the continuous variables, a parametric test (1-way ANOVA) was applied to analyze the data. For the categorical variables, the Fisher exact test and the Pearson chi-square were considered as appropriate. Finally, categorical variables such as alcohol, smoking pain, diabetes mellitus, and exocrine pancreatic insufficiency were considered as binary variables for the statistics.

RESULTS

As reported in Table 1, the 2 groups of subjects studied were comparable for gender (P = 0.316) whereas, as expected, the age of the chronic pancreatitis patients was significantly lower than that of patients having pancreatic ductal adenocarcinoma.
TABLE 2. Correlation Between Age, BMI, and Fecal Elastase-1 Concentrations, and the Substances Studied

|                | Age Coefficient | Age P Value | BMI Coefficient | BMI P Value | Fecal Elastase-1 Coefficient | Fecal Elastase-1 P Value |
|----------------|-----------------|-------------|-----------------|-------------|-----------------------------|--------------------------|
| 25-hydroxyvitamin D | 0.071           | 0.583       | -0.336          | 0.007       | 0.076                       | 0.566                    |
| Calcium         | -0.002          | 0.988       | 0.175           | 0.171       | -0.183                      | 0.152                    |
| Osteocalcin     | -0.038          | 0.767       | -0.175          | 0.169       | -0.141                      | 0.272                    |
| Bone alkaline phosphatase | 0.235       | 0.064       | 0.195           | 0.126       | 0.192                       | 0.132                    |
| PTH             | 0.395           | 0.015       | 0.024           | 0.853       | 0.038                       | 0.769                    |

BMI = body mass index, PTH = parathormone.

(P = 0.005). Exocrine pancreatic insufficiency (fetal elastase 1 < 200 µg/g) was present in 17 patients with chronic pancreatitis and in 1 patient with pancreatic adenocarcinoma (P < 0.001); in particular, fetal elastase 1 concentration < 100 µg/g were present in 5 chronic pancreatitis patients (16.7%). The body mass index (BMI) was similar in the 2 groups of patients (0.752). According to the WHO classification, 31 no differences among the various classes of BMI were observed between the 2 groups of patients (P = 0.204). The imaging studies were compatible with chronic pancreatitis in all patients with chronic pancreatitis as well as in those with pancreatic ductal adenocarcinoma. Histology was carried out in 4 patients with chronic pancreatitis and in all patients with ductal pancreatic adenocarcinoma; 8 patients underwent surgery (2 having chronic pancreatitis and 6 having a pancreatic ductal carcinoma). It should be noted that the 2 patients with chronic pancreatitis had derivative surgery, whereas the 6 patients with pancreatic cancer had resective surgery.

Taking into consideration the clinical variables of all 63 patients studied (Table 2), 25-hydroxyvitamin D was inversely correlated with only the BMI (P = 0.007), whereas it was not correlated with age (P = 0.583) and fetal elastase-1 concentrations (P = 0.556). Regarding the other substances studied, PTH was positively correlated with only the age of the patients (P = 0.015).

As reported in Table 3, of the 5 substances studied, only bone alkaline phosphates were significantly different (P < 0.001) between patients with chronic pancreatitis (mean ± SD; 12.2 ± 1.7 µg/mL) and those with pancreatic ductal adenocarcinoma (36.6 ± 2.0 µg/mL).

The 5 substances were also not related to gender, alcohol habit, smoking habit, presence of pain, presence of exocrine pancreatic insufficiency, presence of diabetes mellitus, or surgery (Table 4). Within the 2 groups of patients, the 23 patients with chronic pancreatitis without diabetes mellitus had serum concentrations of 25-hydroxyvitamin D (11.7 ± 7.1 ng/mL) significantly lower (P = 0.045) than those with chronic pancreatitis and diabetes mellitus (13.9 ± 12.3 ng/mL) whereas smokers with pancreatic ductal adenocarcinoma had serum concentrations of calcium (9.9 ± 1.3 mg/dL) significantly higher (P < 0.001) as compared to nonsmokers (9.4 ± 0.5 mg/dL). Within the group of patients with pancreatic ductal adenocarcinoma, there were no differences in serum levels of the 5 markers studied between the 18 patients without metastases and the 15 with metastases (Table 5). No differences in the 5 markers studied were also found between patients with local cancer invasion and those with distant metastases.

Finally, the frequencies of the abnormal values of the 5 substances evaluated in the 2 groups of patients studied are reported in Figure 1. In particular, 26 patients with chronic pancreatitis (86.7%) had deficient levels of 25-hydroxyvitamin D (2, 6.7% had insufficient serum concentrations of this vitamin), 2 (6.7%) had high serum concentrations of this vitamin, and only 2 had normal concentration (6.7%). Twenty-seven patients with pancreatic ductal adenocarcinoma (81.8%) had deficient levels of 25-hydroxyvitamin D, 6 (18.2%) had insufficient levels and none had normal levels. Four patients with chronic pancreatitis (13.3%) and 6 patients with pancreatic ductal adenocarcinoma (18.2%) had low levels of osteocalcin. Two patients with chronic pancreatitis (6.7%) had high serum levels of bone alkaline phosphatases, whereas 25 patients with pancreatic ductal adenocarcinoma (75.8%) had elevated levels of this protein; this difference was statistically significant (P < 0.001). Calcium was normal in all patients with chronic pancreatitis and was abnormally high in 3 patients with pancreatic ductal adenocarcinoma (9.1%). In the chronic pancreatitis group, 3 patients had low levels of PTH, 1 (3.3%) had

TABLE 3. Serum Concentrations of the 5 Substances Studied in Patients With Chronic Pancreatitis and in Those With Pancreatic Ductal Adenocarcinoma

|                         | Chronic Pancreatitis n = 30 | Pancreatic Ductal Adenocarcinoma n = 33 | P Value |
|-------------------------|-----------------------------|----------------------------------------|---------|
| 25-hydroxyvitamin D, µg/L | 12.2 ± 8.4                  | 13.5 ± 6.6                             | 0.504   |
| Calcium                 | 9.3 ± 0.5                   | 9.5 ± 0.7                              | 0.186   |
| Osteocalcin, pg/mL      | 14.9 ± 2.0                  | 11.2 ± 2.0                             | 0.089   |
| Bone alkaline phosphatase, µg/L | 12.2 ± 1.7                | 36.6 ± 2.0                             | <0.001  |
| PTH, pg/mL              | 13.5 ± 2.0                  | 14.9 ± 2.0                             | 0.224   |

Data are reported as means and SDs. The P values are also reported. SD = standard deviation, PTH = parathormone.
elevated levels of this hormone, and 26 patients had normal levels (86.7%); these figures were similar to those found in patients with pancreatic ductal adenocarcinoma (1 patient had low levels, 3.0%, 1 had high levels, 3.0%, and 31 had normal concentrations, 93.9%).

**DISCUSSION**

Improvement of nutritional status significantly decreased risk of mortality independent of sex, previous treatment history, and evidence of biological anticancer activity. This aspect should be taken in consideration in patients with pancreatic cancer and the medical therapy of bone metabolism is a part of the nutritional support.

Data regarding vitamin D deficiency in chronic pancreatitis diseases are still under debate. It is well known that both deficiency of fat-soluble vitamins and decreased bone mineral density are frequently present in chronic pancreatitis patients with and without exocrine insufficiency, suggesting that routine screening to detect altered bone metabolism should be carried out.

Our data confirmed that >90% of chronic pancreatitis patients had deficient or insufficient serum concentrations of 25-hydroxyvitamin D; it was also found that ~13% of them also had low levels of osteocalcin, 7% had high serum levels of bone alkaline phosphatases, whereas calcium was normal in all chronic pancreatitis patients. These results showed that only a low percentage of chronic pancreatitis patients had a severe altered bone metabolism. Considering the clinical variables associated with the 5 substances studied, it was found that only 23 patients with chronic pancreatitis without diabetes mellitus had serum concentrations of 25-hydroxyvitamin D significantly lower than those with chronic pancreatitis and diabetes mellitus. The factors related to an altered bone metabolism are still under debate. Some authors have reported that low fecal elastase-1 correlated with low bone mineral density in conventional x-rays ($P < 0.05$) in chronic pancreatitis patients, and that patients receiving pancreatic enzyme replacement therapy had significantly higher dual-energy x-ray absorption values; the same results have been obtained by others. However, the results of a meta-analysis have shown that factors other than pancreatic insufficiency are related to the high risk of osteoporosis in chronic pancreatitis patients, and our data confirmed these results. It has been reported that altered bone turnover in chronic pancreatitis is associated with both smoking, and systemic inflammation was identified. Moreover, our results regarding the smoking habit and low levels of vitamin D seems to be different and we need of more studies on this topic.

Regarding patients affected by pancreatic ductal adenocarcinoma, it was also found that ~82% of these subjects had deficient levels of 25-hydroxyvitamin D and 18% had insufficient levels. Approximately 20% had low levels of osteocalcin and 76% had elevated levels of alkaline phosphatase; this latter figure was significantly higher as compared to chronic pancreatitis patients. Finally, calcium was abnormally high in ~9% of the patients with pancreatic ductal adenocarcinoma and these patients could have a paraneoplastic syndrome. In pancreatic cancer patients, the results of a systemic review have shown that dietary vitamin D or circulating concentrations of 25-hydroxyvitamin D are not associated with the risk of pancreatic cancer. Other authors have found that, in men, there is an increased risk of pancreatic cancer associated with currently recommended dietary vitamin D intake levels; no associations with vitamin D intake were observed among women. On the contrary, a genetic study found that 2 high-risk genotypes (ie Ffbb and Ffbb) had an 11.66 and 6.42-fold increased risk of pancreatic cancer, respectively; furthermore, vitamin D receptor gene polymorphisms were important in the development of pancreatic cancer. Others have also confirmed these data suggesting that some variants in vitamin D-related genes may

---

**TABLE 4.** Significance of the Relationship Between the 5 Substances and Gender, Classes of Body Mass Index (BMI), Alcohol Habit, Smoking Habit, Pain, Exocrine Pancreatic Insufficiency, and Diabetes

| Substance             | Gender | BMI | Alcohol | Smoking | Pain | EPI | Diabetes | Calcifications | Surgery |
|-----------------------|--------|-----|---------|---------|------|-----|----------|---------------|---------|
| 25-hydroxyvitamin D   | 0.418  | 0.697 | 0.848 | 0.625  | 0.605 | 0.700 | 0.572    | 0.917          | 0.883   |
| Calcium               | 0.369  | 0.096 | 0.513 | 0.357  | 0.794 | 0.456 | 0.509    | 0.506          | 0.229   |
| Osteocalcin           | 0.162  | 0.621 | 0.902 | 0.801  | 0.411 | 0.268 | 0.868    | 0.622          | 0.958   |
| Bone alkaline phosphatase | 0.141 | 0.797 | 0.920 | 0.595  | 0.580 | 0.649 | 0.557    | 0.241          | 0.956   |
| PTH                   | 0.788  | 0.167 | 0.214 | 0.859  | 0.784 | 0.800 | 0.817    | 0.117          | 0.952   |

BMI = body mass index, EPI = exocrine pancreatic insufficiency, PTH = parathormone.

---

**TABLE 5.** Serum Concentrations of the 5 Substances Studied in Patients with Pancreatic Ductal Adenocarcinoma With and Without Metastases

| Substance             | Patients With Metastases n = 18 | Patients Without Metastases n = 15 | P Value |
|-----------------------|---------------------------------|------------------------------------|---------|
| 25-Hydroxyvitamin D, µg/L | 14.52 ± 7.6                     | 12.2 ± 5.2                         | 0.098   |
| Calcium               | 9.3 ± 0.6                        | 9.9 ± 0.7                          | 0.771   |
| Osteocalcin, pg/mL    | 10.8 ± 2.1                       | 10.2 ± 1.8                        | 0.485   |
| Bone alkaline phosphatase, µg/L | 40.0 ± 2.0                  | 29.7 ± 1.9                        | 0.815   |
| PTH, pg/mL            | 18.4 ± 1.8                       | 13.1 ± 1.8                        | 0.996   |

Data are reported as mean ± standard deviation. The P values are also reported. PTH = parathormone.
influence pancreatic cancer risk. Several cancers have shown an increased risk associated with low vitamin D levels, suggesting that vitamin D supplementation may be an optimal strategy to reduce the risk of different malignancies. On the other hand, it has also been reported\(^\text{25}\) that high vitamin D levels may be associated with an increased risk of pancreatic; in fact, high vitamin D binding protein concentrations may sequester more $25(OH)D$ and reduce free $25(OH)D$ bioavailability. It is possible that, in our patients with pancreatic cancer, bone metabolism was altered and this alteration was probably due to the reduced alimentary introduction of vitamin D and calcium; this was supported by the fact that we found an inverse relationship between vitamin D and the body mass index.

One bias of this study is that we have not evaluated both serum C-terminal cross-linking telopeptide of type I collagen (CTX-1) as a marker of bone resorption and serum procollagen type I N propeptide (s-PINP) as a marker of bone formation\(^\text{26}\); however, we have used only osteocalcin and, although this is appropriate, we believe that because bone metabolism is a coupled process, measurement of both CTX-1 and s-PINP is important to better understand the world of bone metabolism in patients with chronic diseases of the pancreas and we believe that this aspect requires further study.

In conclusion, an altered bone metabolism seems to be associated with chronic diseases of the pancreas, but the mechanism should be better elucidated because low serum levels are

**FIGURE 1.** Individual values of the 5 substances studied in patients with chronic pancreatitis and in those with pancreatic ductal adenocarcinoma. The horizontal dashed lines represent the limits of 25-hydroxyvitamin D: “deficient” (<20.0 ng/mL), “insufficient” (between 20.0 and 30.0 ng/mL) and optimal levels (>30.0 ng/mL); the horizontal dashed lines of calcium, parathormone (PTH), and bone alkaline phosphatase represent the upper and low reference limits; the horizontal solid line of osteocalcin represents the lower normal limit in men and the horizontal dashed line, the lower normal limit in women. PTH = parathormone.
REFERENCES

1. Pezzilli R, Andriulli A, Bassi C, et al., Exocrine Pancreatic Insufficiency collaborative (EPIc) Group. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. World J Gastroenterol. 2013;19:7930–7946.

2. Girgis CM, Baldock PA, Downes M. Vitamin D, muscle and bone: Integrating effects in development, aging and injury. Mol Cell Endocrinol. 2015;410:3–10.

3. Barassi A, Porreca W, De Pasquale L, et al. Use of intraoperative samples to optimize efficacy of central laboratory parathyroid hormone analyses. Clin Chem. 2007;53:535–536.

4. De Pasquale L, Gobatti D, Ravini ML, et al. Intra-operative testing for parathyroid hormone: the Central Laboratory option. J Endocrinol Invest. 2008;31:62–67.

5. Alselami NM, Noureldeen AF, Al-Ghamdi MA, et al. Bone turnover biomarkers in obese postmenopausal Saudi women with type-II diabetes mellitus. Afr Health Sci. 2015;15:90–96.

6. Franck H, Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis. 1993;52:343–346.

7. Fu SW, Zeng GF, Zong SH, et al. Systematic review and meta-analysis of the bone protective effect of phytoestrogens on osteoporosis in ovariectomized rats. Nutr Res. 2014;34:467–477.

8. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005;26:97–122.

9. Pezzilli R, Barassi A, Corsi MM, et al. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol. 2010;45:93–99.

10. Pezzilli R, Barassi A, Morselli-Labate AM, et al. Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. J Gastroenterol. 2007;42:754–760.

11. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. Geneva, Switzerland: WHO Press; 2000.

12. Vashi P, Popiel B, Lammersfeld C, et al. Outcomes of systematic nutritional assessment and medical nutrition therapy in pancreatic cancer. Pancreas. 2015.

13. Joshi A, Reddy SV, Bhatia V, et al. High prevalence of low bone mineral density in patients with tropical calcific pancreatitis. Pancreas. 2011;40:762–767.

14. Duggan SN, O’Sullivan M, Hamilton S, et al. Patients with chronic pancreatitis are at increased risk for osteoporosis. Pancreas. 2012;41:1119–1124.

15. Sikkens EC, Cahn DL, Koch AD, et al. The prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis. Pancreatology. 2013;13:238–242.

16. Haas S, Krins S, Knauerhase A, et al. Altered bone metabolism and bone density in patients with chronic pancreatitis and pancreatic exocrine insufficiency. JOP. 2015;16:58–62.

17. Mann ST, Stracке H, Lange U, et al. Alterations of bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis. Metabolism. 2003;52:579–585.

18. Duggan SN, Smyth ND, Murphy A, et al. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:219–228.

19. Duggan SN, Purcell C, Kilbane M, et al. An association between abnormal bone turnover, systemic inflammation, and osteoporosis in patients with chronic pancreatitis: a case-matched study. Am J Gastroenterol. 2015;110:336–345.

20. Piemonte S, Romagnoli E, Cipriani C, et al. Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. Eur J Endocrinol. 2013;170:K1–4.

21. Liu SL, Zhao YP, Dai MH, et al. Vitamin D status and the risk of pancreatic cancer: a meta-analysis. Clin Med J (Engl). 2013;126:3356–3359.

22. Zablotska LB, Gong Z, Wang F, et al. Vitamin D, calcium, and retinol intake, and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control. 2011;22:91–100.

23. Li L, Wu B, Yang L, et al. Association of vitamin D receptor gene polymorphisms with pancreatic cancer: a pilot study in a North China Population. Oncol Lett. 2013;5:1731–1735.

24. Anderson LN, Cotterchio M, Knight JA, et al. Genetic variants in vitamin D pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada. PLoS One. 2013;8:e66768.

25. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, et al. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res. 2012;72:1190–1198.

26. Vasikaran S, Cooper C, Eastell R, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011;49:1271–1274.